Sclérodermie systémique
Veille bibliographique : Sclérodermie systémique
Les articles sont classés du plus ancien au plus récent, n’hésitez pas à utiliser la barre de recherche pour filtrer les résultats par date par exemple.
| Moinzadeh P et al. Disease progression in systemic sclerosis-overlap syndrome is significantly different from limited and diffuse cutaneous systemic sclerosis. Ann Rheum Dis. 2015 Apr;74(4):730-7. | Lire le résumé |
| Bernstein EJ et al. Survival of adults with systemic sclerosis following lung transplantation: a nationwide cohort study. Arthritis Rheumatol. 2015 May;67(5):1314-22. | Lire le résumé |
| Avouac J et al. Cardiac Biomarkers in Systemic Sclerosis: Contribution of High-Sensitivity Cardiac Troponiin in Addition to N-Terminal Pro-Brain Natriuretic Peptide. Arthritis Care Res (Hoboken). 2015 Jul;67(7):1022-30. | Lire le résumé |
| Wirz EG et al. ; EUSTAR coauthors. Incidence and predictors of cutaneous manifestations during the early course of systemic sclerosis: a 10-year longitudinal study from the EUSTAR database. Ann Rheum Dis. 2015 Jul 31. | Lire le résumé |
| Paik JJ et al. Spectrum of Muscle Histopathologic Findings in Forty-Two Scleroderma Patients With Weakness. Arthritis Care Res (Hoboken). 2015 Oct;67(10):1416-25 | Lire le résumé |
| Avouac J et al. Autoantibodies against Endothelin 1 Type A Receptor Are Strong Predictors of Digital Ulcers in Systemic Sclerosis.Arthritis Care Res (Hoboken). J Rheumatol. 2015 Oct;42(10):1801-7. | Lire le résumé |
| Nagaraja V et al ; Old medications and new targeted therapies in systemic sclerosis. Rheumatology (Oxford). 2015 Nov;54(11):1944-53 | Lire le résumé |
| Suliman YA et al. Brief Report: Pulmonary Function Tests: High Rate of False-Negative Results in the Early Detection and Screening of Scleroderma-Related Interstitial Lung Disease. Arthritis Rheumatol. 2015 Dec;67(12):3256-61 | Lire le résumé |
| Avouac J et al. Joint and tendon involvement predict disease progression in systemic sclerosis: a EUSTAR prospective study. Ann Rheum Dis. janv 2016;75(1):103‑9. | Lire le résumé |
| Mihai C et al. Digital ulcers predict a worse disease course in patients with systemic sclerosis. Ann Rheum Dis. avr 2016;75(4):681‑6. | Lire le résumé |
| Hurabielle C et al. Skin Telangiectasia and the Identification of a Subset of Systemic Sclerosis Patients With Severe Vascular Disease. Arthritis Care Res. juill 2016;68(7):1021‑7. | Lire le résumé |
| Stamm A et al. Exercise pulmonary haemodynamics predict outcome in patients with systemic sclerosis. Eur Respir J. 6 oct 2016 | Lire le résumé |
| Daoussis D et al. A multicenter, open-label, comparative study of B-cell depletion therapy with Rituximab for systemic sclerosis-associated interstitial lung disease. Semin Arthritis Rheum. 2017 Apr;46(5):625-631 | Lire le résumé |
| Hoffmann-Vold A-M et al. Cardiopulmonary Disease Development in Anti-RNA Polymerase III-positive Systemic Sclerosis: Comparative Analyses from an Unselected, Prospective Patient Cohort. J Rheumatol. 2017 Jan 15 | Lire le résumé |
| Herrick et al. “Treatment Outcome in Early Diffuse Cutaneous Systemic Sclerosis: The European Scleroderma Observational Study (ESOS).” Annals of the Rheumatic Diseases, February 10, 2017. | Lire le résumé |
| Sanges S et al. Intravenous immunoglobulins in systemic sclerosis: Data from a French nationwide cohort of 46 patients and review of the literature. Autoimmun Rev. 13 févr 2017. | Lire le résumé |
| Man A et al. Development and validation of a patient-reported outcome instrument for skin involvement in patients with systemic sclerosis. Ann Rheum Dis. 2017 Feb 17. | Lire le résumé |
| Goh NS et al. Short term pulmonary function trends are predictive of mortality in interstitial lung disease associated with systemic sclerosis. Arthritis Rheumatol Hoboken NJ. 2017 Apr 20 | Lire le résumé |
| Volkmann ER et al. Mycophenolate versus Placebo for Systemic Sclerosis-Related Interstitial Lung Disease: An Analysis of Scleroderma Lung Studies I and II. Arthritis Rheumatol Hoboken NJ. 4 avr 2017 | Lire le résumé |
| Andracco R et al. The cumulative number of micro-haemorrhages and micro-thromboses in nailfold videocapillaroscopy is a good indicator of disease activity in systemic sclerosis: a validation study of the NEMO score. Arthritis Res Ther. 2017 Jun 13;19(1):133 | Lire le résumé |
| Vigone B et al. Preliminary safety and efficacy profile of prucalopride in the treatment of systemic sclerosis (SSc)-related intestinal involvement: results from the open label cross-over PROGASS study. Arthritis Res Ther. 2017 Jun 20;19(1):145. | Lire le résumé |
| Le Gouellec N et al. Predictors of lung function test severity and outcome in systemic sclerosis-associated interstitial lung disease. PloS One. 2017;12(8):e0181692. | Lire le résumé |
| Gaine S et al. Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension. Eur Respir J. 2017 Aug;50(2). | Lire le résumé |
| Eyraud A et al. Efficacy and safety of autologous haematopoietic stem cell transplantation in systemic sclerosis: A systematic review of literature. Br J Dermatol. 2017 Sep 14 | Lire le résumé |
| Martis N et al. Limited Exercise Capacity in Patients with Systemic Sclerosis: Identifying Contributing Factors with Cardiopulmonary Exercise Testing. J Rheumatol. 2017 Nov 1 | Lire le résumé |
| Sullivan KM. et al. Myeloablative autologous stem-cell transplantation for severe scleroderma. N Engl J Med 2018;378:35-47. | Lire le résumé |
| Khanna D. et al. Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate). Ann Rheum Dis. 2018;77:212–220. | Lire le résumé |
| Herrick AL et al. Patterns and predictors of skin score change in early diffuse systemic sclerosis from the European Scleroderma Observational Study. Ann Rheum Dis. (in press). | Lire le résumé |
| Coghlan G, Wolf M, Distler O, et al. Incidence of pulmonary hypertension and determining factors in patients with systemic sclerosis. Eur Respir J 2018 | Lire le résumé |
| Thiebaut M, Launay D, Rivière S, Mahévas T, Bellakhal S, Hachulla E, et al. Efficacy and safety of rituximab in systemic sclerosis: French retrospective study and literature review. Autoimmun Rev 2018 | Lire le résumé |
| Igusa Igusa TT, Hummers LK, Visvanathan K, Richardson C, Wigley FM, Casciola-Rosen L, Rosen A, Shah AA. Autoantibodies and scleroderma phenotype define subgroups at high-risk and low-risk for cancer. Ann Rheum Dis. 2018 Apr 20. | Lire le résumé |
| Jaeger VK, Valentini G, Hachulla E, Cozzi F, Distler O, Airó P, et al. Smoking in Systemic Sclerosis: a Longitudinal European Scleroderma Trials and Research Group Study. Arthritis & Rheumatology (Hoboken, NJ). 2018 May 21; | Lire le résumé |
| Jouvray M, Launay D, Dubucquoi S, Sobanski V, Podevin C, Lambert M, et al. Whole-Body Distribution and Clinical Association of Telangiectases in Systemic Sclerosis. JAMA Dermatology. 2018 Jul 1;154(7):796, | Lire le résumé |
| Wu W, Jordan S, Becker MO, Dobrota R, Maurer B, Fretheim H, et al. Prediction of progression of interstitial lung disease in patients with systemic sclerosis: the SPAR model. Annals of the Rheumatic Diseases. 2018 Sep;77(9):1326–32 | Lire le résumé |
| Guler SA, Winstone TA, Murphy D, Hague C, Soon J, Sulaiman N, et al. Does Systemic Sclerosis-Associated Interstitial Lung Disease Burn Out? Specific Phenotypes of Disease Progression. Annals of the American Thoracic Society [Internet]. 2018 Sep 6 [cited 2018 Sep 26]; Available from: https://www.atsjournals.org/doi/10.1513/AnnalsATS.201806-362OC | Lire le résumé |
| Tennøe AH, Murbræch K, Andreassen JC, Fretheim H, Garen T, Gude E, et al. Left Ventricular Diastolic Dysfunction Predicts Mortality in Patients With Systemic Sclerosis. Journal of the American College of Cardiology. 2018 Oct;72(15):1804–13. | Lire le résumé |
| Champtiaux N, Cottin V, Chassagnon G, Chaigne B, Valeyre D, Nunes H, et al. Combined pulmonary fibrosis and emphysema in systemic sclerosis: A syndrome associated with heavy morbidity and mortality. Seminars in Arthritis and Rheumatism [Internet]. 2018 Oct [cited 2018 Nov 26]; Available from: https://linkinghub.elsevier.com/retrieve/pii/S0049017217305115 | Lire le résumé |
| Lescoat A, Yelnik CM, Coiffier G, Wargny M, Lamotte C, Cazalets C, et al. Ulnar Artery Occlusion and severity markers of vasculopathy in Systemic sclerosis: a multicenter cross‐sectional study. Arthritis & Rheumatology [Internet]. 2018 Dec 15 [cited 2018 Dec 19] | Lire le résumé |
| Nagel C, Marra AM, Benjamin N, Blank N, Cittadini A, Coghlan G, et al. Reduced right ventricular output reserve in patients with systemic sclerosis and mildly elevated pulmonary arterial pressures. Arthritis & Rheumatology [Internet]. 2019 Jan 7 [cited 2019 Jan 21]; Available from: http://doi.wiley.com/10.1002/art.40814 | Lire le résumé |
| Young A, Vummidi D, Visovatti S, Homer K, Wilhalme H, White ES, et al. Prevalence, Treatment and Outcomes of Coexistent Pulmonary Hypertension and Interstitial Lung Disease in Systemic Sclerosis. Arthritis & Rheumatology [Internet]. 2019 Feb 14 [cited 2019 Feb 18]; Available from: http://doi.wiley.com/10.1002/art.40862 | Lire le résumé |
| Wu W, Jordan S, Graf N, de Oliveira Pena J, Curram J, Allanore Y, et al. Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort. Ann Rheum Dis. 9 mars 2019 | Lire le résumé |
| Sobanski V, Giovannelli J, Allanore Y, Riemekasten G, Airò P, Vettori S, et al. Phenotypes determined by cluster analysis and their survival in the prospective EUSTAR cohort of patients with systemic sclerosis. Arthritis Rheumatol [Internet]. 10 avr 2019 [cité 23 avr 2019]; Disponible sur: https://onlinelibrary.wiley.com/doi/abs/10.1002/art.40906 | Lire le résumé |
| Elhai M, Boubaya M, Distler O, Smith V, Matucci-Cerinic M, Alegre Sancho JJ, et al. Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study. Ann Rheum Dis. 9 avr 2019;annrheumdis-2018-214816 | Lire le résumé |
| Friedrich S, Lüders S, Glimm AM, Werner SG, Schmittat G, Burmester GR, et al. Association between baseline clinical and imaging findings and the development of digital ulcers in patients with systemic sclerosis. Arthritis Res Ther [Internet]. déc 2019 [cité 16 mai 2019];21(1). Disponible sur: https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-019-1875-1 | Lire le résumé |
| Distler O, Highland KB, Gahlemann M, Azuma A, Fischer A, Mayes MD, et al. Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease. N Engl J Med [Internet]. 20 mai 2019 [cité 24 juin 2019] ; Disponible sur : http://www.nejm.org/doi/10.1056/NEJMoa1903076 | Lire le résumé |
| Becker M, Graf N, Sauter R, Allanore Y, Curram J, Denton CP, et al. Predictors of disease worsening defined by progression of organ damage in diffuse systemic sclerosis: a European Scleroderma Trials and Research (EUSTAR) analysis. Ann Rheum Dis. 21 juin 2019;annrheumdis-2019-215145 | Lire le résumé |
| Gasparini G, Cozzani E, Parodi A. Interleukin-4 and interleukin-13 as possible therapeutic targets in systemic sclerosis. Cytokine. janv 2020;125:154799 | Lire le résumé |
| Valentini G, Huscher D, Riccardi A, Fasano S, Irace R, Messiniti V, et al. Vasodilators and low-dose acetylsalicylic acid are associated with a lower incidence of distinct primary myocardial disease manifestations in systemic sclerosis: results of the DeSScipher inception cohort study. Ann Rheum Dis. 7 août 2019;annrheumdis-2019-215486 | Lire le résumé |
| Morrisroe K, Hansen D, Huq M, Stevens W, Sahhar J, Ngian G, et al. Incidence, risk factors and outcomes of cancer in systemic sclerosis. Arthritis Care Res [Internet]. 20 sept 2019 [cité 23 sept 2019]; | Lire le résumé |
| Khanna D, Spino C, Johnson S, Chung L, Whitfield M, Denton CP, et al. Abatacept in Early Diffuse Cutaneous Systemic Sclerosis – Results of a Phase 2 Investigator‐Initiated, Multicenter, Double‐Blind Randomized Placebo‐Controlled Trial. Arthritis Rheumatol [Internet]. 24 juill 2019 [cité 23 sept 2019]; | Lire le résumé |
| Pacini G, Paolino S, CleliaTrombetta A, Goegan F, Pizzorni C, Alessandri E, et al. Lower urinary tract symptoms in systemic sclerosis: a detailed investigation. Rheumatology [Internet]. 5 oct 2019 [cité 15 oct 2019] | Lire le résumé |
| Nihtyanova SI, Sari A, Harvey JC, Leslie A, Derrett‐Smith EC, Fonseca C, et al. Using autoantibodies and cutaneous subset to develop outcome‐based disease classification in systemic sclerosis. Arthritis Rheumatol [Internet]. 4 nov 2019 [cité 7 nov 2019]; | Lire le résumé |
| Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, et al. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. N Engl J Med. 31 oct 2019;381(18):1718 27 | Lire le résumé |
| Hachulla E, Launay D, Boucly A, Mouthon L, de Groote P, Cottin V, et al. Survival Improved in Patients Aged ≤ 70 Years With Systemic Sclerosis-Associated Pulmonary Arterial Hypertension During the Period 2006 to 2017 in France. Chest [Internet]. nov 2019 [cité 18 déc 2019] | Lire le résumé |
| Henes J, Oliveira MC, Labopin M, Badoglio M, Scherer HU, Del Papa N, et al. Autologous stem cell transplantation for progressive systemic sclerosis: a prospective non-interventional study from the European Society for Blood and Marrow Transplantation Autoimmune Disease Working Party. Haematologica. 16 janv 2020;haematol.2019.230128 | Lire le résumé |
| Ledoult E, Launay D, Béhal H, Mouthon L, Pugnet G, Lega JC, Agard C, Allanore Y, Jego P, Fauchais AL, Harlé JR, Berthier S, Aouba A, Mekinian A, Diot E, Truchetet ME, Boulon C, Duhamel A, Hachulla E, Sobanski V; French National Scleroderma Cohort Network. Early trajectories of skin thickening are associated with severity and mortality in systemic sclerosis. Arthritis Res Ther. 2020 Feb 18;22(1):30 | Lire le résumé |
| Mecoli CA, Shah AA, Boin F, Wigley FM, Hummers LK. The Utility of Plasma Vascular Biomarkers in Systemic Sclerosis: A Prospective Longitudinal Analysis. Arthritis Rheumatol [Internet]. 21 mars 2020 [cité 23 avr 2020] | Lire le résumé |
| Spiera R, Hummers L, Chung L, Frech TM, Domsic R, Hsu V, et al. Safety and efficacy of lenabasum in a phase 2 randomized, placebo‐controlled trial in adults with systemic sclerosis. Arthritis Rheumatol [Internet]. 26 avr 2020 [cité 25 mai 2020] | Lire le résumé |
| Fairchild R, Chung M, Yang D, Sharpless L, Li S, Chung L. Development and Assessment of a Novel Lung Ultrasound Interpretation Criteria for the Detection of Interstitial Lung Disease in Systemic Sclerosis. Arthritis Care Res [Internet]. 31 mai 2020 [cité 15 juin 2020]; | Lire le résumé |
| Khanna D, Allanore Y, Denton CP, Kuwana M, Matucci-Cerinic M, Pope JE, et al. Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial. Ann Rheum Dis. mai 2020;79(5):618‑25. | Lire le résumé |
| Nawata T, Shirai Y, Suzuki M, Kuwana M. Chest wall muscle atrophy as a contributory factor for forced vital capacity decline in systemic sclerosis-associated interstitial lung disease. Rheumatology [Internet]. 23 juill 2020 [cité 19 août 2020] | Lire le résumé |
| Khanna D, Lin CJF, Furst DE, Goldin J, Kim G, Kuwana M, et al. Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med [Internet]. août 2020 [cité 21 sept 2020] | Lire le résumé |
| Landon-Cardinal O, Baril-Dionne A, Hoa S, Meyer A, Leclair V, Bourré-Tessier J, et al. Recognising the spectrum of scleromyositis: HEp-2 ANA patterns allow identification of a novel clinical subset with anti-SMN autoantibodies. RMD Open. sept 2020;6(2):e001357. | Lire le résumé |
| Allanore Y, Wung P, Soubrane C, Esperet C, Marrache F, Bejuit R, et al. A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis. Ann Rheum Dis. déc 2020;79(12):1600‑7 | Lire le résumé |
| Khanna D, Huang S, Lin CJF, Spino C. New composite endpoint in early diffuse cutaneous systemic sclerosis: revisiting the provisional American College of Rheumatology Composite Response Index in Systemic Sclerosis. Ann Rheum Dis. 30 nov 2020;annrheumdis-2020-219100. | Lire le résumé |
| Terrier B, Dechartres A, Gouya H, Ben Arfi M, Bérézne A, Régent A, et al. Cardiac Intravoxel Incoherent Motion Diffusion‐Weighted Magnetic Resonance Imaging With T1 Mapping to Assess Myocardial Perfusion and Fibrosis in Systemic Sclerosis: Association With Cardiac Events From a Prospective Cohort Study. Arthritis Rheumatol. sept 2020;72(9):1571‑80. | Lire le résumé |
| 1. Franks JM, Martyanov V, Wang Y, Wood TA, Pinckney A, Crofford LJ, et al. Machine learning predicts stem cell transplant response in severe scleroderma. Ann Rheum Dis. déc 2020;79(12):1608‑15. 2.Sullivan KM , Goldmuntz EA, Keyes-Elstein L, McSweeney PA, Pinckney A, Welch B, et al. Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma. N Engl J Med. 4 janv 2018;378(1):35‑47. 3.Milano A , Pendergrass SA, Sargent JL, George LK, McCalmont TH, Connolly MK, et al. Molecular Subsets in the Gene Expression Signatures of Scleroderma Skin. Butler G, éditeur. PLoS ONE. 16 juill 2008;3(7):e2696. 4.Franks JM , Martyanov V, Cai G, Wang Y, Li Z, Wood TA, et al. A Machine Learning Classifier for Assigning Individual Patients With Systemic Sclerosis to Intrinsic Molecular Subsets. Arthritis Rheumatol. oct 2019;71(10):1701‑10. | Lire le résumé |
| Assassi S, Li N, Volkmann ER, Mayes MD, Rünger D, Ying J, et al. Predictive Significance of Serum Interferon Inducible Protein Score for Response to Treatment in Systemic Sclerosis Related Interstitial Lung Disease. Arthritis Rheumatol [Internet]. 21 déc 2020 [cité 22 janv 2021]; | Lire le résumé |
| Boudigaard SH, Schlünssen V, Vestergaard JM, Søndergaard K, Torén K, Peters S, et al. Occupational exposure to respirable crystalline silica and risk of autoimmune rheumatic diseases: a nationwide cohort study. Int J Epidemiol [Internet]. 18 janv 2021 [cité 22 févr 2021]; | Lire le résumé |
| Adler BL, Boin F, Wolters PJ, Bingham CO, Shah AA, Greider C, et al. Autoantibodies targeting telomere-associated proteins in systemic sclerosis. Ann Rheum Dis. 25 janv 2021;annrheumdis-2020-218918 | Lire le résumé |
| Hoffmann-Vold A-M, Allanore Y, Alves M, Brunborg C, Airó P, Ananieva LP, et al. Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database. Ann Rheum Dis. févr 2021;80(2):219‑27. | Lire le résumé |
| Zamanian RT, Badesch D, Chung L, Domsic RT, Medsger T, Pinckney A, et al. Safety and Efficacy of B-Cell Depletion with Rituximab for the Treatment of Systemic Sclerosis Associated Pulmonary Arterial Hypertension: A Multi-center, Double-blind, Randomized, Placebo-controlled Trial. Am J Respir Crit Care Med. 2 mars 2021;rccm.202009-3481OC. | Lire le résumé |
| Roofeh D, Lin CJF, Goldin J, Kim GH, Furst DE, Denton CP, et al. Tocilizumab Prevents Progression of Early Systemic Sclerosis Associated Interstitial Lung Disease. Arthritis Rheumatol [Internet]. 3 févr 2021 [cité 23 mars 2021]; | Lire le résumé |
| Young A, Moles VM, Jaafar S, Visovatti S, Huang S, Vummidi D, et al. Performance of the DETECT Algorithm for Pulmonary Hypertension Screening in a Systemic Sclerosis Cohort. Arthritis Rheumatol [Internet]. 24 mars 2021 [cité 1 avr 2021]; | Lire le résumé |
| Fibroblast activation protein: a serine protease expressed at the remodeling interface in idiopathic pulmonary fibrosis. Hum Pathol. mars 2006;37(3):352‑60. (PubMed) Bergmann C, Distler JHW, Treutlein C, Tascilar K, Müller A-T, Atzinger A, et al. 68Ga-FAPI-04 PET-CT for molecular assessment of fibroblast activation and risk evaluation in systemic sclerosis-associated interstitial lung disease: a single-centre, pilot study. Lancet Rheumatol. mars 2021;3(3):e185‑94. (The Lancet) | Lire le résumé |
| Foeldvari I, Culpo R, Sperotto F, Anton J, Avcin T, Baildam E, et al. Consensus-based recommendations for the management of juvenile systemic sclerosis. Rheumatology. 6 avr 2021;60(4):1651‐8. | Lire le résumé |
| Ebata S, Yoshizaki A, Oba K, Kashiwabara K, Ueda K, Uemura Y, et al. Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial. Lancet Rheumatol [Internet]. mai 2021 [cité 22 juin 2021]; | Lire le résumé |
| Jaafar S, Lescoat A, Huang S, Gordon J, Hinchcliff M, Shah AA, et al. Clinical characteristics, visceral involvement, and mortality in at-risk or early diffuse systemic sclerosis: a longitudinal analysis of an observational prospective multicenter US cohort. Arthritis Res Ther [Internet]. déc 2021 [cité 6 juill 2021];23(1). | Lire le résumé |
| Chassagnon, Guillaume, Maria Vakalopoulou, Alexis Régent, Evangelia I. Zacharaki, Galit Aviram, Charlotte Martin, Rafael Marini, et al. « Deep Learning–Based Approach for Automated Assessment of Interstitial Lung Disease in Systemic Sclerosis on CT Images ». Radiology: Artificial Intelligence 2, no 4 (1 juillet 2020): e190006. | Lire le résumé |
| 1. Siegert E, Uruha A, Goebel H-H, Preuße C, Casteleyn V, Kleefeld F, et al. Systemic sclerosis-associated myositis features minimal inflammation and characteristic capillary pathology. Acta Neuropathol (Berl). juin 2021;141(6):917‑27. 2. Ellezam B, Leclair V, Troyanov Y, Meyer A, Hudson M, Landon-Cardinal O. Capillary basement membrane reduplication in myositis patients with mild clinical features of systemic sclerosis supports the concept of ‘scleromyositis’. Acta Neuropathol (Berl). août 2021;142(2):395‑7. " | Lire le résumé |
| Kuwana M, Allanore Y, Denton CP, Distler JH, Steen V, Khanna D, et al. Nintedanib in patients with systemic sclerosis‐associated interstitial lung disease: subgroup analyses by autoantibody status and skin score. Arthritis Rheumatol. 12 sept 2021;art.41965. | Lire le résumé |
| Hoa S, Lazizi S, Baron M, Wang M, Fritzler MJ, Hudson M, et al. Association between autoantibodies in systemic sclerosis and cancer in a national registry. Rheumatology. 2 oct 2021;keab735. | Lire le résumé |
| Chauvelot L, Gamondes D, Berthiller J, Nieves A, Renard S, Catella‐Chatron J, et al. Hemodynamic Response to Treatment and Outcomes in Pulmonary Hypertension Associated With Interstitial Lung Disease Versus Pulmonary Arterial Hypertension in Systemic Sclerosis: Data From a Study Identifying Prognostic Factors in Pulmonary Hypertension Associated With Interstitial Lung Disease. Arthritis Rheumatol. févr 2021;73(2):295‑304. ( | Lire le résumé |
| Khanna D, Lin CJF, Furst DE, Wagner B, Zucchetto M, Raghu G, et al. Long-Term Safety and Efficacy of Tocilizumab in Early Systemic Sclerosis–Interstitial Lung Disease: Open Label Extension of a Phase 3 Randomized Controlled Trial. Am J Respir Crit Care Med. 1 déc 2021;rccm.202103-0714OC. | Lire le résumé |
| Hinze AM, Perin J, Woods A, Hummers LK, Wigley FM, Mukherjee M, et al. Diastolic Dysfunction in Systemic Sclerosis: Risk Factors and Impact on Mortality. Arthritis Rheumatol. 20 déc 2021;art.42054. | Lire le résumé |
| 1.Skaug B , Lyons MA, Swindell WR, Salazar GA, Wu M, Tran TM, et al. Large-scale analysis of longitudinal skin gene expression in systemic sclerosis reveals relationships of immune cell and fibroblast activity with skin thickness and a trend towards normalisation over time. Ann Rheum Dis. 22 déc 2021;annrheumdis-2021-221352. 2.the French National Scleroderma Cohort Network , Ledoult E, Launay D, Béhal H, Mouthon L, Pugnet G, et al. Early trajectories of skin thickening are associated with severity and mortality in systemic sclerosis. Arthritis Res Ther. déc 2020;22(1):30. 3.Hinchcliff M , Huang C-C, Wood TA, Matthew Mahoney J, Martyanov V, Bhattacharyya S, et al. Molecular Signatures in Skin Associated with Clinical Improvement during Mycophenolate Treatment in Systemic Sclerosis. J Invest Dermatol. août 2013;133(8):1979‑89. 4.Stifano G , Sornasse T, Rice LM, Na L, Chen-Harris H, Khanna D, et al. Skin Gene Expression Is Prognostic for the Trajectory of Skin Disease in Patients With Diffuse Cutaneous Systemic Sclerosis. Arthritis Rheumatol. juin 2018;70(6):912‑9. 5.Khanna D , Spino C, Johnson S, Chung L, Whitfield ML, Denton CP, et al. Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator‐Initiated, Multicenter, Double‐Blind, Randomized, Placebo‐Controlled Trial. Arthritis Rheumatol. janv 2020;72(1):125‑36. 6. Skaug B, Khanna D, Swindell WR, Hinchcliff ME, Frech TM, Steen VD, et al. Global skin gene expression analysis of early diffuse cutaneous systemic sclerosis shows a prominent innate and adaptive inflammatory profile. Ann Rheum Dis. mars 2020;79(3):379‑86. | Lire le résumé |
| Ebata S, Yoshizaki A, Oba K, Kashiwabara K, Ueda K, Uemura Y, et al. Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial. Lancet Rheumatol. juill 2021;3(7):e489‑97. | Lire le résumé |
| Bellando-Randone S, Del Galdo F, Lepri G, Minier T, Huscher D, Furst DE, et al. Progression of patients with Raynaud’s phenomenon to systemic sclerosis: a five-year analysis of the European Scleroderma Trial and Research group multicentre, longitudinal registry study for Very Early Diagnosis of Systemic Sclerosis (VEDOSS). Lancet Rheumatol. déc 2021;3(12):e834‑43. | Lire le résumé |
| Cosse C, Kernéis S, Lescoat A, Pugnet G, Truchetet M, Priollet P, et al. Osteitis in Systemic Sclerosis: A Nationwide Case–Control Retrospective Study. Arthritis Care Res. mai 2022;74(5):809‑17. | Lire le résumé |
| Assassi S, Volkmann ER, Zheng WJ, Wang X, Wilhalme H, Lyons MA, Roth MD, Tashkin DP. Peripheral blood gene expression profiling shows predictive significance for response to mycophenolate in systemic sclerosis-related interstitial lung disease. Ann Rheum Dis. 2022 Feb 21:annrheumdis-2021-221313. doi: 10.1136/annrheumdis-2021-221313 | Lire le résumé |
| Khanna D, Lin CJF, Furst DE, Wagner B, Zucchetto M, Raghu G, et al. Long-Term Safety and Efficacy of Tocilizumab in Early Systemic Sclerosis–Interstitial Lung Disease: Open-Label Extension of a Phase 3 Randomized Controlled Trial. Am J Respir Crit Care Med. 15 mars 2022;205(6):674‑84 | Lire le résumé |
| Hou Z, Su X, Han G, Xue R, Chen Y, Chen Y, et al. JAK1/2 Inhibitor Baricitinib Improves Skin Fibrosis and Digital Ulcers in Systemic Sclerosis. Front Med. 6 juin 2022;9:859330 | Lire le résumé |
| Senet P, Maillard H, Diot E, Lazareth I, Blaise S, Arnault J, et al. Efficacy and Safety of Botulinum Toxin in Adults with Raynaud’s Phenomenon Secondary to Systemic Sclerosis: A Randomized, Double‐Blind, Placebo‐Controlled Multicenter Study. Arthritis Rheumatol. 6 sept 2022;art.42342 | Lire le résumé |
| Hoffmann-Vold AM, Brunborg C, Airò P, Ananyeva LP, Czirják L, Guiducci S, et al. Cohort enrichment strategies for progressive interstitial lung disease in systemic sclerosis from EUSTAR. Chest. 13 oct 2022;S0012-3692(22)03925-3. | Lire le résumé |
| Foeldvari I, Klotsche J, Kasapcopur O, Adrovic A, Terreri MT, Sakamoto AP, et al. Differences Sustained Between Diffuse and Limited Forms of Juvenile Systemic Sclerosis in an Expanded International Cohort. Arthritis Care Res. oct 2022;74(10):1575‑84 | Lire le résumé |
| Volkmann ER, Kreuter M, Hoffmann-Vold AM, Wijsenbeek M, Smith V, Khanna D, et al. Dyspnoea and cough in patients with systemic sclerosis–associated interstitial lung disease in the SENSCIS trial. Rheumatology. 2 nov 2022;61(11):4397‑408 | Lire le résumé |
| Volkmann ER, Kreuter M, Hoffmann-Vold AM, Wijsenbeek M, Smith V, Khanna D, et al. Dyspnoea and cough in patients with systemic sclerosis–associated interstitial lung disease in the SENSCIS trial. Rheumatology. 2 nov 2022;61(11):4397‑408. | Lire le résumé |
| Khanna D, Denton CP, Furst DE, Mayes MD, Matucci-Cerinic M, Smith V, de Vries D, Ford P, Bauer Y, Randall MJ, Ebrahimpoor M, Kupcsik L, Stiers PJ, Deberdt L, Prasad N, Lim S, Pujuguet P, Ahmed S. A 24-Week, Phase IIa, Randomized, Double-blind, Placebo-controlled Study of Ziritaxestat in Early Diffuse Cutaneous Systemic Sclerosis (NOVESA). Arthritis Rheumatol. 2023 Feb 14. doi: 10.1002/art.42477. Epub ahead of print. PMID: 36787101 | Lire le résumé |
| Herrick AL, Batta R, Overbeck K, Raud J, Manning J, Murray A, Dinsdale G, Tornling G. A phase 2 trial investigating the effects of the angiotensin II type 2 receptor agonist C21 in systemic sclerosis-related Raynaud's. Rheumatology (Oxford). 2023 Feb 1;62(2):824-828. doi: 10.1093/rheumatology/keac426. PMID: 35894657; PMCID: PMC9891408. | Lire le résumé |
| Hoeper MM, Badesch DB, Ghofrani HA, Gibbs JSR, Gomberg-Maitland M, McLaughlin VV, Preston IR, Souza R, Waxman AB, Grünig E, Kopeć G, Meyer G, Olsson KM, Rosenkranz S, Xu Y, Miller B, Fowler M, Butler J, Koglin J, de Oliveira Pena J, Humbert M; STELLAR Trial Investigators. Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension. N Engl J Med. 2023 Apr 20;388(16):1478-1490. doi: 10.1056/NEJMoa2213558. Epub 2023 Mar 6. PMID: 36877098 | Lire le résumé |
| Lescoat A, Huscher D, Schoof N, Airò P, de Vries-Bouwstra J, Riemekasten G, Hachulla E, Doria A, Rosato E, Hunzelmann N, Montecucco C, Gabrielli A, Hoffmann-Vold AM, Distler O, Ben Shimol J, Cutolo M, Allanore Y; EUSTAR collaborators. Systemic sclerosis-associated interstitial lung disease in the EUSTAR database: analysis by region. Rheumatology (Oxford). 2023 Jun 1;62(6):2178-2188. doi: 10.1093/rheumatology/keac576. Erratum in: Rheumatology (Oxford). 2023 Jun 09;: PMID: 36222557. | Lire le résumé |
| Iglesias M, Torre-Villalvazo I, Butrón-Gandarillas P, Rodríguez-Reyna TS, Torre-Anaya EA, Guevara-Cruz M, et al. Adipose derived stromal vascular fraction and fat graft for treating the hands of patients with systemic sclerosis. A randomized clinical trial. PloS One. 2023;18(8):e0289594. Park Y, Lee YJ, Koh JH, Lee J, Min HK, Kim MY, et al. Clinical Efficacy and Safety of Injection of Stromal Vascular Fraction Derived from Autologous Adipose Tissues in Systemic Sclerosis Patients with Hand Disability: A Proof-Of-Concept Trial. J Clin Med. 19 sept 2020;9(9):3023. Granel B, Daumas A, Jouve E, Harlé JR, Nguyen PS, Chabannon C, et al. Safety, tolerability and potential efficacy of injection of autologous adipose-derived stromal vascular fraction in the fingers of patients with systemic sclerosis: an open-label phase I trial. Ann Rheum Dis. déc 2015;74(12):2175‑82. | Lire le résumé |
| Mankikian J, Caille A, Reynaud-Gaubert M, Agier MS, Bermudez J, Bonniaud P, et al. Rituximab and mycophenolate mofetil combination in patients with interstitial lung disease (EVER-ILD): a double-blind, randomised, placebo-controlled trial. Eur Respir J. juin 2023;61(6):2202071. | Lire le résumé |
| Keret S, Henig I, Zuckerman T, Kaly L, Shouval A, Awisat A, et al. Outcomes in progressive systemic sclerosis treated with autologous hematopoietic stem cell transplantation compared with combination therapy. Rheumatol Oxf Engl. 6 sept 2023;kead457 | Lire le résumé |
| Kwon OC, Han K, Park MC. Risk of kidney failure in patients with systemic sclerosis: a nationwide population-based study. RMD Open. nov 2023;9(4):e003490 | Lire le résumé |
| Distler O, Bonderman D, Coghlan JG, Denton CP, Grünig E, Khanna D, et al. Performance of DETECT PAH algorithm according to the hemodynamic definition of pulmonary arterial hypertension (PAH) in the 2022 ESC/ERS guidelines: Early detection of pulmonary arterial hypertension in systemic sclerosis patients. Arthritis Rheumatol Hoboken NJ. 25 déc 2023; | Lire le résumé |
| Volkmann ER, McMahan ZH, Smith V, Jouneau S, Miede C, Alves M, et al. Risk of Malnutrition in Patients With Systemic Sclerosis‐Associated Interstitial Lung Disease Treated With Nintedanib in the Randomized, Placebo‐Controlled SENSCIS Trial. Arthritis Care Res. déc 2023;75(12):2501‑7 | Lire le résumé |
| Ghuman A, Khanna D, Lin CJF, Furst DE, Raghu G, Martinez FJ, et al. Prognostic and predictive markers of systemic sclerosis-associated interstitial lung disease in a clinical trial and long-term observational cohort. Rheumatology. 1 févr 2024;63(2):472‑81 | Lire le résumé |